Benitec Biopharma Inc.

NASDAQ (USD): Benitec Biopharma Inc. (BNTC)

Last Price

11.41

Today's Change

-0.76 (6.24%)

Day's Change

11.41 - 12.40

Trading Volume

401,448

Profile
BNTC

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Jerel A. Banks M.D., Ph.D. Dr. Jerel A. Banks M.D., Ph.D.

Full Time Employees:  16 16

IPO Date:  2014-06-24 2014-06-24

CIK:  0001808898 0001808898

ISIN:  US08205P2092 US08205P2092

CUSIP:  08205P100 08205P100

Beta:  0.88 0.88

Last Dividend:  0.00 0.00

Dcf Diff:  5.18 5.18

Dcf:  6.23 6.23

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Address

3940 Trust Way,
Hayward, CA 94545, US

510 780 0819

http://benitec.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment